Schick delisted from Nasdaq
Schick Technologies has been delisted from the Nasdaq stock exchange, the company has reported. On Sept. 15, Schick received notice from the Nasdaq Listing Qualifications Panel that as of close of business, Schick’s common stock would no longer be
Schick Technologies has been delisted from the Nasdaq stock exchange, the company has reported. On Sept. 15, Schick received notice from the Nasdaq Listing Qualifications Panel that as of close of business, Schicks common stock would no longer be traded on the exchange. The panel attributed its decision to Schicks inability to file its 10-K for fiscal 1999 (end-March) on time, as well as factors discussed in Schicks 8-K, filed on Sept. 2.
Schick will request a review of the panels decision within the 15-day limit required by Nasdaqs marketplace rules, and plans to file its 10-K and its 10-Q for the quarter ended June 30 as soon as the firms new accountants, Grant Thornton, complete their audit of Schicks financial statements. Schicks former accounting firm, PricewaterhouseCoopers, resigned as the companys independent accountants on Aug. 25. Schick will seek relisting on the exchange, or apply for listing on another exchange, once its filings are current with the Securities and Exchange Commission, according to the Long Island City, NY-based company.
Newsletter
Stay at the forefront of radiology with the Diagnostic Imaging newsletter, delivering the latest news, clinical insights, and imaging advancements for today’s radiologists.
Key MRI Findings Predictive of Treatment Response for Unresectable Hepatocellular Carcinoma
July 14th 2025For patients with unresectable hepatocellular carcinoma, a pre-treatment MRI finding of LI-RADS tumor in vein was associated with over an 86 percent lower likelihood of responding to transcatheter arterial chemoembolization (TACE) and targeted immunotherapy.
